检索结果 - Saibah Chohan
- Showing 1 - 3 results of 3
-
1
-
2
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative... 由 Adam Brufsky, S.B. Kim, Zanete Zvirbule, Alexandru Eniu, Jeroen Mebis, Joohyuk Sohn, Matthew Wongchenko, Saibah Chohan, Reena Amin, Y. Yan, Virginia McNally, David Miles, Sherene Loi
出版 2021Artigo -
3
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG) 由 Ami V. Desai, Giles Robinson, Karen Gauvain, Ellen M. Basu, Margaret E. Macy, Luke Maese, Nicholas Whipple, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed S Abdelbaki, Amy E. Armstrong, Thomas F. Cash, Christine A. Pratilas, Nadège Corradini, Lynley V. Marshall, Mufiza Farid‐Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses‐Lorente, Alison K. Cardenas, Katherine E. Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
出版 2022Artigo
相关主题
Cancer
Internal medicine
Medicine
Oncology
Adenocarcinoma
Adverse effect
Atezolizumab
Bioinformatics
Biology
Breast cancer
Cancer research
Cell culture
Cohort
Computational biology
Gene
Genetics
Immunotherapy
Neural crest
Neuroblastoma
Pediatric cancer
Pembrolizumab
ROS1
Taxane
Tolerability
Triple-negative breast cancer
microRNA